Incretin - Wikipedia
Frontiers | GLP-1 based therapeutics: simultaneously combating T2DM and obesity | Neuroscience
Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice - Li - 2015 - Journal of Neurochemistry - Wiley Online Library
Victoza® (liraglutide) injection 1.2 mg or 1.8 mg Mechanism of Action
GLP-1 analogs
Dipeptidyl peptidase-4 inhibitor Glucagon-like peptide-1 receptor agonist Liraglutide Dulaglutide, others, angle, text, pharmaceutical Drug png | PNGWing
Novo Nordisk: Make-And-Take Strategy For The Obesity Drug Market (NYSE:NVO) | Seeking Alpha
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology
Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension | Arteriosclerosis, Thrombosis, and Vascular Biology
Neuroprotective and anti‐apoptotic effects of liraglutide on SH‐SY5Y cells exposed to methylglyoxal stress - Sharma - 2014 - Journal of Neurochemistry - Wiley Online Library
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? | SpringerLink
Mechanistic insights into how Liraglutide aids in remission of Diabetes: Liraglutide (brand name: Victoza, Saxenda and others), a drug used in the treatment of type II diabetes, increases Pax6 and insulin expression,
Liraglutide Mechanism of Action for Weight Loss (Obesity) and Diabetes
Recent updates on GLP-1 agonists: Current advancements & challenges - ScienceDirect
Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes - Endotext - NCBI Bookshelf
The 10+ Benefits of Liraglutide — MyBioHack | Unlock Your Maximus Potential
Mechanism of Action of Liraglutide Drug Paper
Glucagon-like peptide-1 (GLP-1) AGONIST - Incretin Mimetics - GlobalRPH
Short‐acting glucagon‐like peptide‐1 receptor agonists as add‐on to insulin therapy in type 1 diabetes: A review - Albèr - 2017 - Diabetes, Obesity and Metabolism - Wiley Online Library
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release - ScienceDirect
Approaches for half-life extension of GLP-1 agonists. (a) Liraglutide... | Download Scientific Diagram
How Victoza® Works | Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg | Diabetology & Metabolic Syndrome | Full Text
The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways | Scientific Reports
![Victoza (Liraglutide [rDNA] Injection): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/victoza1.gif "Victoza (Liraglutide [rDNA] Injection): Uses, Dosage, Side Effects, Interactions, Warning")